GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
6.62
+0.09 (1.38%)
At close: Jul 3, 2025, 1:00 PM
6.55
-0.07 (-1.06%)
After-hours: Jul 3, 2025, 4:53 PM EDT
GlucoTrack Employees
GlucoTrack had 11 employees as of December 31, 2024. The number of employees increased by 5 or 83.33% compared to the previous year.
Employees
11
Change (1Y)
5
Growth (1Y)
83.33%
Revenue / Employee
n/a
Profits / Employee
-$2,409,364
Market Cap
3.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GCTK News
- 10 days ago - Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday? - Benzinga
- 10 days ago - Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 23 days ago - Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements - GlobeNewsWire
- 4 weeks ago - Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 5 weeks ago - Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - GlobeNewsWire
- 6 weeks ago - Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - GlobeNewsWire
- 7 weeks ago - Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - GlobeNewsWire